Chinese researchers have developed an innovative patient-derived tumor spheroid (PDTS) model that could enhance precision medicine approaches for brain cancer patients. The study, conducted at China Medical University Hospital, demonstrates the potential of using 3D biomimetic platforms to test drug responses in metastatic brain tumors, offering a new tool for personalizing cancer treatment strategies.
Delta-Fly Pharma's DFP-14927, a drug delivery formulation of DFP-10917, is undergoing an expanded Phase I study in R/R colorectal cancer patients at MD Anderson and UCLA.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.